$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
How much money do you still need to pay after medical insurance reimburses ceritinib?
2025-10-19 11:44:20
Check Details
How much does an individual pay out of pocket for ceritinib after being covered by medical insurance?
2025-10-19 11:44:20
Check Details
Does ceritinib have an effect on ROS1-rearranged non-small cell lung cancer?
2025-10-19 11:44:20
Check Details
Is ceritinib covered by national medical insurance?
2025-10-19 11:44:20
Check Details
Xakorui’s medical insurance reimbursement ratio in 2021
2025-10-19 11:44:20
Check Details
Ceritinib has significant effect in treating crizotinib-resistant patients
2025-10-19 11:44:20
Check Details
Medical insurance reimbursement requirements for Xalkori (crizotinib)
2025-10-19 11:44:20
Check Details
Can Xekori (crizotinib capsules) be reimbursed by medical insurance?
2025-10-19 11:44:20
Check Details
Safety, efficacy and tolerability of ceritinib in the treatment of ALK-positive non-small cell lung cancer_ Kanghule
2025-10-19 11:44:20
Check Details
Xalkori also has a significant anti-cancer effect on ROS1-rearranged advanced non-small cell lung cancer
2025-10-19 11:44:20
Check Details
U.S. FDA grants Xalkori (crizotinib) breakthrough drug status
2025-10-19 11:44:20
Check Details
The effectiveness of Xalkori in the first-line treatment of advanced non-small cell lung cancer
2025-10-19 11:44:20
Check Details
1
2
...
3907
3908
3909
3910
3911
3912
3913
...
4152
4153
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
The Cornerstone Therapy for Adrenocortical Carcinoma and Global Guidelines Update
2
Trodelvy® (Sacituzumab Govitecan-hziy): A Life-Changing ADC for Advanced Cancers
3
A Revolutionary Targeted Therapy for Hematological Malignancies
4
A New Option for Advanced Renal Cell Carcinoma Treatment
5
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
6
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:
7
Sacituzumab Govitecan: Trop-2 Targeted ADC Clinical Medication Guide
8
Fulvestrant (Faslodex) Breast Cancer Guide: Indications, Dosage and Safety Specifications
9
Adagrasib (Krazati): Full Guide to KRAS G12C Inhibitor for Cancer Treatment
10
Comprehensive Analysis of the Third-Generation EGFR-TKI
11
ATOMIC Study: Atezolizumab Plus Chemo Improves DFS in dMMR Stage III Colon Cancer
12
Oncology Immunotherapy vs Anti-Inflammatory Biologic: Dostarlimab vs Secukinumab - A Mechanism-Centered Comparison